Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)
I'm LongbridgeAI, I can summarize articles.Bank of America Securities has reaffirmed a Buy rating on Inhibikase Therapeutics (IKT) with a price target of $6.00, while the stock closed at $1.86. Analyst Jason Zemansky, a 5-star analyst, reports a Strong Buy consensus with an average price target of $6.20, indicating a 233.33% upside. LifeSci Capital also maintains a Buy rating with a $5.00 target.
In a report released yesterday, Jason Zemansky from Bank of America Securities maintained a Buy rating on Inhibikase Therapeutics, with a price target of $6.00. The company’s shares closed yesterday at $1.86.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Zemansky is a 5-star analyst with an average return of 19.9% and a 56.33% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Biogen, Insmed, and Ligand Pharma.
Currently, the analyst consensus on Inhibikase Therapeutics is a Strong Buy with an average price target of $6.20, a 233.33% upside from current levels. In a report released on May 13, LifeSci Capital also maintained a Buy rating on the stock with a $5.00 price target.